Sponsors
The bill seeks to lower many veterans' drug costs and make VA drug purchasing more consistent through a national formulary and negotiated deals, but those savings and efficiencies come with risks of reduced access for some patients, higher costs for non‑preferred drugs, added administrative burdens, and less transparent net pricing.
Veterans will likely pay less for many medications and face lower 30-day copays for generics and national‑formulary drugs because the VA can negotiate supplemental discounts, formulary‑preference deals, and value‑based contracts.
VA drug spending, prescribing, and procurement may become more consistent and efficient—through a codified national formulary, volume contracts, blanket purchase agreements, and periodic reviews—potentially reducing waste and lowering taxpayer burden.
Veterans could gain clearer, standardized access and predictability about which medications are covered by a codified national formulary, making it easier to understand benefits and prescribing expectations.
Some veterans risk losing access to drugs they currently receive or seeing coverage restricted if the formulary is codified or if manufacturers decline preferred‑status deals and products are moved off the formulary.
Veterans who need brand‑name or non‑formulary drugs will face higher 30‑day copayments, increasing out‑of‑pocket costs for those individuals.
Implementing and administering the formulary system, negotiating and monitoring value‑based contracts, and staffing the advisory committee will create administrative costs and operational burdens that could divert VA resources or take time to realize benefits.
Based on analysis of 4 sections of legislative text.
Codifies a VA national formulary, authorizes negotiations for discounts and value‑based deals, adds tiered copayments, and creates a temporary advisory committee.
Introduced December 10, 2025 by Mariannette Miller-Meeks · Last progress December 10, 2025
Creates a codified VA national formulary, gives the Secretary of Veterans Affairs explicit authority to negotiate supplemental discounts, formulary‑preference agreements, and value‑based purchasing arrangements with drug and biologic manufacturers, and establishes a tiered copayment schedule that lowers copays for 30‑day supplies of generics and national formulary drugs. It also requires periodic outcome and budget reviews of major formulary actions and sets up a temporary Veterans Formulary Advisory Committee to provide veteran and clinician input on formulary changes.